Rosiglitazone (Avandia®, Avandamet®) will be the subject of the current affairs programme Panorama tonight. In particular the programme appears to be drawing attention to the cardiovascular risks of the drug and also to the ongoing safety review.
The European Medicines Agency has announced an additional meeting to review the complex data in order to finalise the review of rosiglitazone in time for the next scheduled meeting of 20-23 September 2010.
Panorama also claims that the Commission for Human Medicines, an advisory committee to the Medicines and Healthcare product Regulatory Agency (MHRA), voted unanimously in July for rosiglitazone to be withdrawn from the market. The contents of these meetings normally remain confidential until a full review is completed since it may not be in the public interest to release such information until the regulatory process being completed.
Action: Clinicians should be aware of this programme. Patients who are taking rosiglitazone currently may seek advice or request an alternative.
|« Bisphosphonates and cancer risk||Rosiglitazone in the BMJ »|